Foghorn Therapeutics (FHTX)
(Real Time Quote from BATS)
$5.33 USD
+0.29 (5.75%)
Updated Aug 8, 2024 01:44 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 41 - 60 ( 79 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Foghorn Showcase Degraders Capability and New CBP Program at TPD Summit; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Glimpse into BRD9 Clinical Profile with PD Data; New Selective CBP Program
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 Goes to Full Hold in AML; Uveal Melanoma Study Remains On Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financials; Data in 2023 for BRD9 Degrader Program FHD-609
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Pipeline Remains On Track, Expect AML/MDS Clinical Hold to be Released Near Term; Reit. Buy and Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286?s Partial Clinical Hold is More Reflective of Targeting AML Over BAF; Reit. Buy and Lowering Our PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Partial Clinical Hold for FHD-286 in r/r AML; We See a Short Study Delay
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Focus Remains on De-risking BAF platform; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials; Initial FHD-286 Ph 1 Data Ahead in 2H:22
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; Well Positioned Ahead of Initial Data for FHD-286 and FHD-609
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
BAF Is Up to Bat-Initial Phase 1 Data Across Multiple Programs in 1H22; Reit Buy and $25PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A